Please assess the completion status of the following clinical trial:

Trial Title: Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Documented HIV-1 infection~* Initiation of ART through a government-sponsored ART program at least six months prior~* Undetectable HIV viral load (\< 400 copies/mL)~* CD4 count \> 250/mm3~* TS prophylaxis prescribed for at least the previous 2 months~* Intention to remain in the study area until the end of the study period~* Informed consent from participant~* Female study volunteers of reproductive potential must have a negative urine pregnancy test performed within 20 days before randomization.~* Female study volunteers of reproductive potential who participate in sexual activity that could lead to pregnancy must use contraception (male or female condoms, diaphragm or cervical cap with spermicide, intrauterine device, or hormone-based contraceptive) while receiving their assigned study drug and for one month after stopping the medications.~Exclusion Criteria:~* Severe acute illness (defined as requiring hospitalization at the time of screening or other conditions such as laboratory abnormalities as determined by the investigators)~* Chronic treatment (requiring therapy for \> 14 days) or secondary prophylaxis (for toxoplasmosis, Pneumocystis pneumonia, or tuberculosis for example) with any drug with antimalarial or antibacterial activity~* History of hypersensitivity to antifolate drugs or CQ~* Laboratory exclusion criteria~* Hemoglobin \< 8.0 gm/dL~* Platelet count \< 50,000/mm3~* Absolute granulocyte count \< 500/mm3~* Serum alanine aminotransferase (ALT) concentration \> 210 U/L for men, \>160 U/L for women~* Serum creatinine concentration \> 3.3mg/dl (291.7µmol/L) for men, and \> 2.7mg/dl (238.7µmol/L) for women)~* History of visual field or retinal changes~* History of preexisting auditory damage~* History of porphyria~* History of psoriasis~* History of liver disease~* History of seizure disorder~* History of glucose-6-phosphate dehydrogenase (G6PD) deficiency~* History of ECG and cardiac conduction abnormality or cardiomyopathy~* History of myopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care Prophylaxis (TS) (Type: ACTIVE_COMPARATOR): Standard of care prophylaxis with daily trimethoprim sulfamethoxazole (TS).
- Chloroquine (CQ) prophylaxis (Type: EXPERIMENTAL): Discontinuation of standard of care TS prophylaxis and starting weekly chloroquine prophylaxis
- Discontinuation of standard of care (Type: NO_INTERVENTION): Control arm - Discontinuation of standard of care trimethoprim sulfamethoxazole.

Based on this trial design, predict the completion outcome and termination type (if applicable).